ArticleERJ open research2019
Prevalence of oral corticosteroid use in the German severe asthma population.
Article in ERJ open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pooled it
- Between Guidelines and Daily Practice: The Persistent Use of Parenteral Depot Corticosteroids in Germany.Clinical and translational allergy · 2026Article
- [Care for uncontrolled asthma in Germany - with focus on Magdeburg and Mannheim regions].Deutsche medizinische Wochenschrift (1946) · 2026Article
- Review
- Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS).Pneumologie (Stuttgart, Germany) · 2025Article
- Maintenance OCS Were Used More Frequently Than Biologics in Patients with Uncontrolled GINA 4/5 Asthma in Germany in 2019.Journal of asthma and allergy · 2024Article
- Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.Allergologie select · 2024Review
- Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study.Respiration; international review of thoracic diseases · 2024Article
- A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma.Advances in therapy · 2023Review
- [Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)].Pneumologie (Stuttgart, Germany) · 2023Article
- Roles of real-world evidence in severe asthma treatment: challenges and opportunities.ERJ open research · 2023Article
- Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany.Journal of asthma and allergy · 2023Article
- Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2022Article
- Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity.Journal of personalized medicine · 2022Review
- Characteristics of Oral Corticosteroid Users Among Persons with Asthma on GINA Step 3 Therapy and Above: A Cross-Sectional Study in Portuguese Community Pharmacies.Journal of asthma and allergy · 2022Article
- Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany.Journal of asthma and allergy · 2022Article
- Real-life Cretan asthma registry focused on severe asthma: On behalf of 'The Cretan registry of the use of Biologics in Severe Asthma'.Experimental and therapeutic medicine · 2021Article
- Patients' experiences of asthma exacerbation and management: a qualitative study of severe asthma.ERJ open research · 2021Article
- Precision medicine reaching out to the patients in allergology - a German-Japanese workshop report.Allergologie select · 2021Article
- Persistent Uncontrolled Asthma: Long-Term Impact on Physical Activity and Body Composition.Journal of asthma and allergy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe investigated the prevalence of severe asthma, its comorbidities, and especially the use of oral corticosteroid (OCS) therapy in patients with severe asthma.
methodsPooled data from 3 961 429 patients insured (with statutory health insurance) during the year 2015 were analysed. Prevalence rates of severe asthma and its OCS-associated comorbidities in patients on high-dosage (HD) inhaled corticosteroid (ICS) in combination with a long-acting β agonist (LABA) therapy were compared with those of patients who were also treated with OCSs.
resultsThe asthma prevalence was 7.3%, of which 8.7% (0.6% absolute) were treated with HD-ICS/LABAs. Of these, 33.6% received additional OCSs with calculated dosages between 0.9 and 9.1 mg·day
conclusionThe analyses show that OCSs are frequently prescribed in patients receiving HD-ICS/LABAs because of severe asthma and are they are frequently associated with adverse effects commonly reported with steroid usage. These data support a necessary change in severe asthma treatment, which is reflected in current treatment guidelines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.